{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-005450","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2025-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.554281+00:00","generated_at":"2026-05-27T00:57:32.390061+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"bioAffinity receives Nasdaq delisting notice for bid price below $1.00","bullets":["Received Nasdaq notice on Feb 7, 2025; common stock bid price below $1.00 for 30 consecutive business days.","Has 180-day compliance period until Aug 6, 2025 to regain minimum $1.00 closing bid price.","No immediate effect on listing or trading; stock continues on Nasdaq Capital Market under BIAF.","Company to consider available options to regain compliance; may be eligible for additional time if not compliant by August.","Potential failure to cure could result in delisting if not resolved."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-005450","json":"https://secwatch.observer/filing/0001493152-25-005450.json","markdown":"https://secwatch.observer/filing/0001493152-25-005450.md","text":"https://secwatch.observer/filing/0001493152-25-005450.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225005450/0001493152-25-005450-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225005450/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:57:32.390061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce61a348a997e5fa37a5ded044b9cc675ae76c2d","claim":"bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225005450/0001493152-25-005450-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-063806","ticker":"ILLR","company_name":"Triller Group Inc.","filed_at":"2026-06-02T12:26:59+00:00","headline":"Triller gets Nasdaq bid-price exception until June 30, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063806","json":"https://secwatch.observer/filing/0001213900-26-063806.json","markdown":"https://secwatch.observer/filing/0001213900-26-063806.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/ea0292925-8k_triller.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225005450/0001493152-25-005450-index.htm","comparable_excerpt":"May 29, 2026, the Nasdaq Hearings Panel (the\n“Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant\nTriller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30,\n2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following\na successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which\nmodified a previous December 26, 2025 decision by a Nasdaq Hearings Panel","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1769624/000121390026063806/0001213900-26-063806-index.htm"}},{"accession":"0001213900-26-063575","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-06-01T21:00:15+00:00","headline":"iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063575","json":"https://secwatch.observer/filing/0001213900-26-063575.json","markdown":"https://secwatch.observer/filing/0001213900-26-063575.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/ea0292875-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225005450/0001493152-25-005450-index.htm","comparable_excerpt":"May 29, 2026, iSpecimen Inc. (the “Company”)\nreceived a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum\nof $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report\non Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May\n29, 2026, the Company doe","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm"}},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225005450/0001493152-25-005450-index.htm","comparable_excerpt":"May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm"}},{"accession":"0001493152-26-026520","ticker":"NUTR","company_name":"NUSATRIP Inc","filed_at":"2026-06-01T11:10:27+00:00","headline":"NusaTrip receives Nasdaq delinquency notice for late 10-K and 10-Q; faces delisting if not compliant by Oct 12, 2026","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026520","json":"https://secwatch.observer/filing/0001493152-26-026520.json","markdown":"https://secwatch.observer/filing/0001493152-26-026520.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/0001493152-26-026520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225005450/0001493152-25-005450-index.htm","comparable_excerpt":"May 27, 2026, NusaTrip Incorporated (the “Company”) received a delinquency notification letter (the “Notice”)\nfrom the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s\nnon-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely\nfile its Annual Report on Form 10-K for the period ended December 31, 2025 and its Quarterly Report on Form 10-Q for the period ended\nMarch 31, 2026 (collectively, the “Delinquent Filings”). The Listing Rule requires listed companies to timely file all req","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2006468/000149315226026520/0001493152-26-026520-index.htm"}},{"accession":"0001213900-26-063141","ticker":"XXI","company_name":"Twenty One Capital, Inc.","filed_at":"2026-06-01T11:05:20+00:00","headline":"Twenty One Capital receives NYSE non-compliance notice; audit committee lacks independence; cure due June 5","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063141","json":"https://secwatch.observer/filing/0001213900-26-063141.json","markdown":"https://secwatch.observer/filing/0001213900-26-063141.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026063141/0001213900-26-063141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026063141/ea0292652-8ka1_twenty.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225005450/0001493152-25-005450-index.htm","comparable_excerpt":"cator\nand website references will be removed when the Company regains compliance with all NYSE quantitative and corporate governance listing\nstandards. The Company expects to appoint, as soon as practicable, an additional member to the audit committee who meets the independence\nrequirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the Listed Company Manual. Forward-Looking Statements Certain statements in this periodic report are “forward-looking\nstatements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words indi","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026063141/0001213900-26-063141-index.htm"}},{"accession":"0001213900-26-063100","ticker":"COLA","company_name":"Columbus Acquisition Corp/Cayman Islands","filed_at":"2026-05-30T01:56:47+00:00","headline":"Columbus Acquisition regains compliance with Nasdaq $50M MVLS rule; delisting risk removed","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063100","json":"https://secwatch.observer/filing/0001213900-26-063100.json","markdown":"https://secwatch.observer/filing/0001213900-26-063100.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2028201/000121390026063100/0001213900-26-063100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2028201/000121390026063100/ea0292674-8k_columbus.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225005450/0001493152-25-005450-index.htm","comparable_excerpt":"May 28, 2026, the Company the Company received a written notice from Nasdaq notifying the Company that the Staff has determined that\nfor the last 10 consecutive business days, from May 13, 2026 to May 27, 2026, the Company’s MVLS has been $50 million or greater.\nAccordingly, the Company has regained compliance with the MVLS Rule and the Staff has indicated that the matter is now closed. 1 SIGNATURES Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized. Columbus\n Acq","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028201/000121390026063100/0001213900-26-063100-index.htm"}},{"accession":"0001493152-26-026442","ticker":"HWH","company_name":"HWH International Inc.","filed_at":"2026-05-29T21:21:49+00:00","headline":"HWH International receives Nasdaq deficiency notice for equity below $2.5M threshold","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026442","json":"https://secwatch.observer/filing/0001493152-26-026442.json","markdown":"https://secwatch.observer/filing/0001493152-26-026442.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226026442/0001493152-26-026442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226026442/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225005450/0001493152-25-005450-index.htm","comparable_excerpt":"May 29, 2026 HWH International Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’\nequity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) because the Company’s stockholders’\nequity of $2,078,220 as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 was below the\nrequired minimum of $2.5 million, and because, as of May 29, 2026, the Company did","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226026442/0001493152-26-026442-index.htm"}},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315225005450/0001493152-25-005450-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}